The KLHL13 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung carcinoma epithelial line. Generated via CRISPR/Cas9-mediated disruption of the KLHL13 gene, this product yields a heterogeneous pool of cells carrying loss-of-function mutations. The polyclonal format allows for robust population-level analyses and assessment of phenotypic variability associated with KLHL13 ablation. This ready-to-use cell stock is suitable for downstream functional studies without requiring clonal isolation.
A-549 cells, derived from a lung carcinoma of a 58-year-old Caucasian male, serve as a classic model for type II alveolar epithelial cells and lung adenocarcinoma. These adherent epithelial cells display features of alveolar type II pneumocytes, including lamellar body formation, and are extensively employed in respiratory disease and cancer research. Their stable karyotype and well-annotated genome facilitate genetic engineering. In the context of KLHL13 knockout, A-549 cells offer a physiologically relevant background to explore ubiquitin-dependent mitotic control in lung adenocarcinoma, a disease frequently associated with cell cycle defects.
KLHL13 functions as a substrate-specific adaptor for the Cullin3-RING E3 ubiquitin ligase complex comprising CUL3 and RBX1. It selectively targets proteins such as Aurora B kinase (AURKB) for K48-linked polyubiquitination and proteasomal degradation, a process essential for proper mitotic progression and cytokinesis. KLHL13 expression is transcriptionally regulated by E2F family members in a cell cycle-dependent manner, linking its activity to proliferative cues. During mitosis, KLHL13 dimerizes with KLHL9 to enhance substrate recognition, mediating timely destruction of Aurora B to prevent chromosomal missegregation and genomic instability.
In A-549 lung adenocarcinoma cells, disruption of KLHL13 impairs the ubiquitin-proteasome pathway, likely stabilizing Aurora B and other mitotic regulators. This can lead to aberrant spindle assembly, cytokinesis failure, and altered proliferation, allowing dissection of mitotic vulnerabilities in cancer. The polyclonal model reflects tumor heterogeneity, enabling study of clonal variation in response to KLHL13 loss and assessment of therapeutic sensitivities, such as resistance to mitotic inhibitors or proteasome drugs.
Key applications include Western blotting for KLHL13 and Aurora B to verify knockout efficiency, flow cytometry for cell cycle profiling, and immunofluorescence to visualize mitotic defects. Proliferation (MTT, BrdU) and apoptosis assays quantify functional outcomes, while RNA-seq and ubiquitination assays provide mechanistic insights. This polyclonal knockout model is ideal for high-throughput screening of mitotic regulators and validating therapeutic targets in lung adenocarcinoma. For additional information, please contact Ascent Research.
